HTG Molecular Diagnostics (HTGM) Stock Rating Lowered by Zacks Investment Research

HTG Molecular Diagnostics (NASDAQ:HTGM) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Friday.

According to Zacks, “HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona. “

Other research analysts have also issued research reports about the company. ValuEngine upgraded HTG Molecular Diagnostics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. HC Wainwright set a $6.00 price objective on shares of HTG Molecular Diagnostics and gave the stock a “buy” rating in a research note on Wednesday, December 27th. Finally, Canaccord Genuity raised their price objective on shares of HTG Molecular Diagnostics to $5.00 in a research note on Friday, January 5th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $5.19.

HTG Molecular Diagnostics (HTGM) traded down $0.07 during trading hours on Friday, reaching $3.64. The company’s stock had a trading volume of 1,390,000 shares, compared to its average volume of 1,190,000. The company has a market capitalization of $41.67 and a PE ratio of -1.43. HTG Molecular Diagnostics has a twelve month low of $1.20 and a twelve month high of $13.25.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Vanguard Group Inc. increased its holdings in HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 135,234 shares of the medical research company’s stock after buying an additional 37,841 shares during the period. Vanguard Group Inc. owned about 1.42% of HTG Molecular Diagnostics worth $359,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 15.15% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/01/14/htg-molecular-diagnostics-htgm-stock-rating-lowered-by-zacks-investment-research.html.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Get a free copy of the Zacks research report on HTG Molecular Diagnostics (HTGM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for HTG Molecular Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply